Short-term effects of felodipine in hypertensive type II diabetic males on sulfonylurea treatment.
OBJECTIVE
To study the effects on blood pressure and glucose homeostasis of felodipine, a calcium antagonist.


METHODS
A double-blind randomized cross-over study comparing felodipine ER and placebo.


METHODS
A university centre of diabetic care in Malmö, Sweden.


METHODS
Seventeen hypertensive type II diabetic males on oral sulfonylurea (glibenclamide) treatment.


METHODS
Four-week treatment periods separated by a 2-week wash-out period. Felodipine 10-20 mg once daily was given.


METHODS
Blood pressure, heart rate, HbA1c and response to oral glucose tolerance test; glucose, insulin and c-peptide. Measured before randomization and at the end of each double-blind treatment period.


RESULTS
Blood pressure was significantly reduced during felodipine treatment and heart rate slightly increased. Felodipine did not influence insulin or c-peptide levels. There was no significant change in glucose levels but an increase in HbA1c.


CONCLUSIONS
The study demonstrated that felodipine is an effective agent for type II diabetic patients on glibenclamide treatment. The effect on HbA1c is noteworthy even if not of clinical significance in the short term. Controlled long-term studies in diabetic patients are needed to fully evaluate antihypertensive agents.
Kjellström
T
T
Department of Medicine, University of Lund, Malmö General Hospital, Sweden.
Blychert
E
E
Lindgärde
F
F
D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002096:C-Peptide / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D004311:Double-Blind Method; D015736:Felodipine / Q000494:pharmacology* / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006441:Hemoglobin A / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013997:Time Factors
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D013453:Sulfonylurea Compounds; D006441:Hemoglobin A; D015736:Felodipine